Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) concerning whether a series of statements by Arrowhead Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 8, 2016, Arrowhead Pharmaceuticals revealed that the U. S. Food & Drug Administration will be placing a clinical hold on the Company’s Heparc-2004 clinical study of ARC-520. According to Arrowhead Pharmaceuticals, the FDA’s clinical hold is likely due to deaths at the highest dose of an ongoing non-human primate toxicology study.

On this news, NASDAQ: ARWR fell from a close of $6.11 per share to a close of $4.45 per share on November 9, 2016.

Based in Pasadena, CA, and founded in 1989 Arrowhead Pharmaceuticals Inc is a biopharmaceutical company, developing novel drugs to treat intractable diseases.

If you purchased shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) on or before November 8, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185